Northwest Biotherapeutics (NWBO) Income from Continuing Operations (2010 - 2026)

Northwest Biotherapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 13246000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 29.96% year-over-year to 13246000.0; the TTM figure through Mar 2026 stood at 71063000.0 (down 4.03% YoY), while the FY2025 annual figure was 60699000.0, up 27.55% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 13246000.0, up from 16126000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 11197000.0 in Q4 2023, with the low at 130235000.0 in Q3 2022.
• The 5-year median for Income from Continuing Operations is 16881000.0 (2024), against an average of 23424647.06.
• The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations plunged 1017.61% in 2022, then surged 88.08% in 2023.
• Northwest Biotherapeutics' Income from Continuing Operations stood at 19039000.0 in 2022, then jumped by 41.19% to 11197000.0 in 2023, then slipped by 19.23% to 13350000.0 in 2024, then decreased by 20.79% to 16126000.0 in 2025, then grew by 17.86% to 13246000.0 in 2026.
• Business Quant data shows NWBO's Income from Continuing Operations at 13246000.0 in Q1 2026, 16126000.0 in Q4 2025, and 16941000.0 in Q3 2025.